Pacira BioSciences (PCRX) Barclays 28th Annual Global Healthcare Conference summary

Strategic initiatives and partnerships

• Rolled out the 5x30 strategy aiming for 3 million patients by 2030, double-digit top-line growth, five-point margin expansion, five pipeline products, and five partnerships.

• Secured key agreements with Johnson & Johnson MedTech to triple ZILRETTA's reach and with LG Chem to expand EXPAREL and ZILRETTA in Asia Pacific.

• Settled with Fresenius, providing IP visibility for EXPAREL through 2039 and strengthening the patent estate.

• Focused on expanding commercial payer coverage and executing GPO contracts to drive volume and pricing improvements.

• Pursuing additional partnerships in Europe, Latin America, and Japan to further global expansion.

Product performance and reimbursement trends

• EXPAREL experienced volume growth above 6% in the last year, up from 3% the previous year, driven by NOPAIN Act reimbursement and GPO contracts.

• NOPAIN Act enabled reimbursement outside bundled payments for Medicare outpatients at ASP +6%, with commercial payers offering up to ASP +29%.

• Total covered lives outside the bundle reached 102 million, with ambitions to expand further this year.

• Price increases were implemented across the product line, and volume is expected to steadily rise, especially after lapping the last GPO contract in June.

• Dedicated sales forces were established for each product to enhance focus and execution.

Market impact and clinician adoption

• Market research survey of 740 clinicians showed high awareness and significant changes in patient management due to NOPAIN.

• Data indicate reduced opioid utilization and improved patient outcomes, supporting the case for maintaining NOPAIN reimbursement.

• Ongoing education efforts target pharmacy directors, billing, and healthcare professionals to maximize uptake.

• Execution and expanded payer coverage are expected to drive further growth in 2026.